H

Hans Biomed Corp
KOSDAQ:042520

Watchlist Manager
Hans Biomed Corp
KOSDAQ:042520
Watchlist
Price: 25 250 KRW -3.44% Market Closed
Market Cap: 341.6B KRW

Net Margin
Hans Biomed Corp

-34.9%
Current
-14%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-34.9%
=
Net Income
-31.3B
/
Revenue
89.8B

Net Margin Across Competitors

No Stocks Found

Hans Biomed Corp
Glance View

Market Cap
327.9B KRW
Industry
Biotechnology

Hans Biomed Corp. engages in the manufacture and sale of graft material and silicon products. The company is headquartered in Seoul, Seoul. The company went IPO on 2009-10-09. The firm mainly provides three categories of products: skin-implant materials, bone-implant materials and silicone products. Its skin-implant materials are used for burn treatment and skin graft under the brand names of SureDerm, BellaGen and GPS. Its bone-implant materials include allogeneic bones, xenogenous bones and synthetic bones used in dentistry, orthopedic and others, which are under the brand names of SureFuse, ExFuse and SureOss. Its silicone products are used for treatments of scars and for breast implant and others, which are under the brand names of BellaGel and Scar Clinic. In addition, it provides hair transplanters and others.

Hans Biomed Corp Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-34.9%
=
Net Income
-31.3B
/
Revenue
89.8B
What is the Net Margin of Hans Biomed Corp?

Based on Hans Biomed Corp's most recent financial statements, the company has Net Margin of -34.9%.

Back to Top